Key result
This study is a protocol for a meta-analysis evaluating the efficacy and safety of Shenfuqiangxin Pills for chronic heart failure, and therefore reports no quantitative results.
Why the study?
Shenfuqiangxin Pills are widely used for chronic heart failure, but strict evidence-based medical evidence evaluating their efficacy and safety is lacking.
Does Shenfuqiangxin Pills (SFQX) improve efficacy and safety in patients with chronic heart failure?
Meta-Analysis
Does Shenfuqiangxin Pills (SFQX) improve efficacy and safety in patients with chronic heart failure?
This protocol outlines a planned systematic review and meta-analysis to evaluate the efficacy and safety of Shenfuqiangxin Pills for chronic heart failure.
Answers are grounded in this paper and cite their sources.
Protocol for SFQX RCT in CHF will deliver needed evidence; leaves open efficacy and safety until completion.
BACKGROUND: As the last link in the chain of cardiovascular events, chronic heart failure (CHF) has high morbidity, high mortality, and poor prognosis. It is one of the main causes of death and disability worldwide. Shenfuqiangxin Pills (SFQX) is widely used as a Chinese herbal medicine (CHM) prescription for CHF, but there is still a lack of strict evidence-based medical evidence. Therefore, we make a protocol for evaluating the efficacy and safety of SFQX for CHF. METHODS: According to the search strategy, randomized controlled trials (RCTs) of SFQX for CHF will be retrieved from 8 databases without limitation of publication date or language. First of all, the literature was screened according to the eligibility criteria, and use the Cochrane Collaboration's tool to assess the quality of the included literature. Then, using software for traditional meta-analysis. Finally, using GRADE method to assess the strength of recommendations. RESULTS: This study will evaluate the efficacy and safety of SFQX for CHF, thereby providing more evidence support for clinical decision-making in CHF. CONCLUSION: Our research will provide more references for the clinical medication of patients with CHF. PROTOCOL REGISTRATION NUMBER: INPLASY202110019.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2021) conducted a meta-analysis in chronic heart failure (CHF). Shenfuqiangxin Pills (SFQX) was evaluated on Efficacy and safety. This study is a protocol for a meta-analysis evaluating the efficacy and safety of Shenfuqiangxin Pills for chronic heart failure, and therefore reports no quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: